- Bill Digest
-
No events on calendar for this bill.
-
Representative Wayne Sasser
Representative Kristin Baker, M.D.
Representative Donna McDowell White
Representative Larry W. Potts
Representative Michael H. Wray
Representative Jeff Zenger
Representative Bill Ward
Representative Ben T. Moss, Jr.
Representative Howard Penny, Jr.
Representative Donny Lambeth
Representative Charles W. Miller
Representative Jay Adams
Representative Rosa U. Gill
Representative Carla D. Cunningham
Representative Joseph Pike
Representative Marvin W. Lucas
Representative William D. Brisson
Representative Allison A. Dahle
Representative Frances Jackson, PhD
Representative Julie von Haefen
Representative Jimmy Dixon
Representative Joe John
Representative Jeffrey C. McNeely
Representative Shelly Willingham
Representative Zack Hawkins
Representative Mike Clampitt
Representative Gloristine Brown
Representative Wesley Harris, PhD
Representative Carolyn G. Logan
Representative Dennis Riddell
Representative Diamond Staton-Williams, RN, BSN, MHA
Representative Diane Wheatley
Representative Cynthia Ball
Representative Allen Buansi
Representative Maria Cervania
Representative Marcia Morey
Representative Frank Sossamon
-
Re-ref Com On Rules, Calendar, and Operations of the HouseHouse | 2023-03-21Reptd Fav Com SubstituteHouse | 2023-03-21Ref to the Com on Health, if favorable, Rules, Calendar, and Operations of the HouseHouse | 2023-03-08Passed 1st ReadingHouse | 2023-03-08FiledHouse | 2023-03-07
-
CONTROLLED SUBSTANCES
HEALTH EDUCATION
HEALTH SERVICES
OCCUPATIONS
PHARMACEUTICALS
PHARMACISTS & PHARMACIES
PUBLIC
PUBLIC HEALTH
PATIENT RIGHTS
-
90 (Chapters); 90-12.8 (Sections)
-
No counties specifically cited.
-
-
-
H287: Educate Patients About Opioid Antagonists. Latest Version
AN ACT requiring health care practitioners and pharmacists to educate patients with prescriptions for opioid pain medications and medications to treat opioid use disorder about the potential dangers of opioids, overdose prevention, and the availability and use of opioid antagonists to prevent overdose deaths.
The General Assembly of North Carolina enacts:
SECTION 1. Article 1 of Chapter 90 of the General Statutes is amended by adding a new section to read:
§ 90‑12.8. Requirement to provide opioid antagonist education.
(a) Consistent with the federal Food and Drug Administration's labeling requirements for opioid pain medication and medication to treat opioid use disorder announced in its Drug Safety Communication dated July 23, 2020, a practitioner as defined in G.S. 90‑87(22) shall do all of the following when issuing a prescription for a Schedule II controlled substance described in G.S. 90‑90(1):
(1) Provide information regarding all of the following to each patient receiving the prescription:
a. The potential dangers of opioids.
b. Overdose prevention.
c. The availability and use of a drug approved by the federal Food and Drug Administration as an opioid antagonist for the complete or partial reversal of opioid‑induced respiratory depression.
(2) Provide the information described in sub‑subdivisions (1)a. through (1)c. of this subsection to one or more persons if designated by the patient receiving the prescription or, for a patient who is a minor, to the minor's parent, guardian, or person standing in loco parentis.
(b) When dispensing a Schedule II controlled substance described in G.S. 90‑90(1), a pharmacy, through a pharmacist or pharmacy personnel, shall do one of the following:
(1) Make available the information described in sub‑subdivisions (a)(1)a. through (a)(1)c. of this section that is consistent with the federal Food and Drug Administration's labeling requirements for opioid pain medication and medication to treat opioid use disorder announced in its Drug Safety Communication dated July 23, 2020.
(2) Post signage in a conspicuous place containing the information described in sub‑subdivisions (a)(1)a. through (a)(1)c. of this section.
(c) Nothing in this section shall be construed to do any of the following:
(1) Limit a practitioner's liability for negligent diagnosis or treatment of a patient, as allowed under applicable State or federal law.
(2) Constitute negligence per se or create a private right of action against any practitioner, including a pharmacy, a pharmacist, or pharmacy personnel, who fails to follow the requirements of this section.
(d) This section shall not apply to a practitioner providing hospice services as defined in G.S. 131E‑201(5b) to a hospice patient as defined in G.S. 131E‑201(4).
SECTION 2. This act becomes effective October 1, 2023.